...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Position Sizing and Odds of Success

 You state eGFR was non-significant at p = .4 yet BearDwnAZ said this:

They all say the same thing. In the rather small post-hoc analysis of 48 CKD patients from combined SUSTAIN (24-week study) and ASSURE (26-week study), there were 13 placebo and 35 apabetalone patients. The apabetalone group increased eGFR by 3.4% vs. baseline, which was significant (p=0.04). 

Share
New Message
Please login to post a reply